Considering offers from two MM investment banks: MTS and Leerink. Any insight into how they are doing (recent activity), quality of MD hires, relative strength in verticals (services, biopharma, etc.)?
Anything is appreciated.
| +409 | Change My Mind: Banks Shouldn’t Hire Foreigners at All | 111 | 15m |
| +176 | Article - UBS’ Investment Bank Keeps Losing Ground | 34 | 9h |
| +95 | Don’t work at UBS - UBS Sucks | 11 | 44m |
| +77 | An Exhaustive Guide: How to Solve Every Single Accretion/Dilution Question | 7 | 2h |
| +51 | When to Leave Office as Intern | 5 | 2d |
| +43 | Best IB Group Overall? | 25 | 1d |
| +34 | Would you rather be a Touse Squid or a Bouse Mogger in IB | 2 | 2d |
| +31 | What do you say to ppl who don’t know EVR/LAZ/CVP/PJT | 22 | 1d |
| +31 | STEM student lost in London IB recruiting | 17 | 19h |
| +20 | Still recruiting SA'27 | 13 | 18h |
Career Resources
Get instant access to lessons taught by experienced private equity pros and bulge bracket investment bankers including financial statement modeling, DCF, M&A, LBO, Comps and Excel Modeling.
^following
Did a coffee chat with someone from MTS years ago, sounded like you can have some say in regards to the vertical you want to focus on (biopharma is historically their best vertical).
Know a few bankers there and one of their partners (ex-BB MD) supposedly was unanimously seen as their biggest rainmaker. Not sure about their recent hires.
I’d say MTS, know several people there and have only heard great things about culture/hours/comp.
Also talked to a VP who used to work for SVB Securities before it went under, he said it was a sweatshop. But that was several years ago and it might be better now after the Leerink re-rebrand idk
MTS for sure
You can literally check online - MTS mostly deals w $100mm or NFP deals (and some Japan stuff). Leerink does better
Leerink recently completely overhauled their M&A team. Their new co-president is one of the co-founders of PJT and they also hired a couple MDs from Guggenheim and Gordan Dyal. They just advised GSK on its acquisition of IDRx, and a few other M&A deals. I imagine they want to climb higher on the M&A LTs. Also they are at the top of the league tables in Biopharma ECM and churn out multiple FOs, PIPEs, ATMs, etc. per month. MTS is strictly M&A and they do a few $1B+ deals a year, I believe. MTS I have heard also has a fantastic culture/comp and Leerink’s has been iffy at times but believe its improving but who knows. If you’re joining Leerink, you may be doing a bit more “building the brand” type work for the M&A side rather than at MTS where they have been mandated a few times on large deals already. Both of them are great choices and good banks within Biopharma.
Aliquam ratione a ratione voluptas beatae doloremque dolorem. Et vero eum qui quos. Doloribus deserunt ut rerum sed. Culpa maxime et consequatur est et aliquam.
Minima nihil mollitia cumque aut quia autem possimus. Consequatur quidem accusamus aut reiciendis. Aliquam vel consequatur nam veritatis perspiciatis ipsam voluptate.
Eum ducimus voluptas atque. Tenetur quia et minima minus dignissimos eaque. Quae vel quisquam amet molestias. Optio sit et non tempore earum odit.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...